Rationale and pharmacology of angiotensin II receptor antagonists: Current status and future issues

Journal of Hypertension, Supplement

Volumn 15, Issue 7, 1997, Pages

  Johnston, Colin I ^a   Naitoh, Mareo ^a   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ACE inhibitors; Angiotensin II receptor antagonists; Hypertension; Irbesartan; Losartan; Renin angiotensin system

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; NEUROTENSIN; PROTEIN; RECEPTOR SUBTYPE; RENIN; SODIUM ION; SUBSTANCE P; TACHYKININ; WATER;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; GLOMERULOSCLEROSIS; HOMEOSTASIS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031427248     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Waeber B, Nussberger J, Brunner HR: Angiotensin-converting enzyme inhibitors in hypertension. In Hypertension: Pathophysiology, Diagnosis and Management, 2nd edn. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2861-2872.
2. Johnston CI: Angiotensin converting enzyme inhibition. In The Renin-Angiotensin System. Edited by Robertson JIS, Nichols MG. London: Gower Medical Publications; 1993:87.1-87.15.
3. Johnston CI, Burrell LM: Evolution of blockade of the renin-angiotensin system. J Hum Hypertens 1995, 9:375-380.
4. Juillerat L, Nussberger J, Menard J, et al.: Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990, 16:564-572.
5. Campbell DJ: Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor Type 1 antagonists. Clin Exp Pharmacol Physiol 1996, 23 (suppl 3):S125-S131.
6. Klickstein LB, Kaempfer CE, Wintroub BU: The granulocyte angiotensin system: angiotensin I converting activity of cathepsin D. J Biol Chem 1982, 357:1504-1506.
7. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A: Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. J Biol Chem 1990, 265:22348-22357.
8. Urata H, Nishimura H, Ganten D: Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996, 9:277-284.
9. Zisman LS, Abraham WT, Meixell GE, et al.: Angiotensin II formation in the intact human heart J Clin Invest 1995, 96:1490-1498.
10. Nishimura H, Hoffmann S, Baltatu O, Sugimura K, Ganten D, Urata H: Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Int 1996, 49 (suppl 55):S18-S23.
11. Pitt B, Segal R, Martinez FA, et al., on behalf of the ELITE study investigators: Randomised trial of Iosartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747-752.
12. Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn FAO: Localization of angiotensin converting enzyme in the rat heart Circ Res 1991, 68:141-149.
13. Zhuo J, Allen AM, Yamada H, Sun Y, Mendelsohn FAO: Localization and properties of the angiotensin-converting enzyme and angiotensin receptors in the heart In The Cardiac Renin-Angiotensin System. Edited by Lindpainter K, Ganten D. New York: Futura Publishing Co., Inc.; 1994:63-88.
14. Chai SY, Johnston CI: Tissue distribution of angiotensin-converting enzyme. In Hypertension: Pathophysiology, Diagnosis and Management, 2nd edn. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995: 1683-1693.
15. Smith RD, Timmermans PBMWM: Human angiotensin receptor subtypes. Curr Opin Nephrol Hypertens 1994, 3:112-122.
16. Abdelrahman AM, Burrell LM, Johnston CI: Blockade of the reninangiotensin system at different sites: effect on renin, angiotensin and aldosterone. V Hypertens 1993, 11 (suppl 3):S23-S26.
17. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:206-251.
18. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD: Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996, 39:625-656.
19. Johnston CI: Angiotensin receptor antagonists: focus on Iosartan. Lancet 1995, 346:1403-1407.
20. Cazaubon C, Gougat J, Bousquet F, et al.: Pharmacological characterization of SR 47436, a new nonpeptide AT, subtype angiotensin II receptor antagonist J Pharmacol Exp Ther 1993, 265:826-834.
21. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994, 251:143-150.
22. Christophe B, Líbon R, Cazaubon C, Nisato D, Manning A, Chatelain P: Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-Induced presser responses in the pithed rat: potential mechanisms of action. Eur J Pharmacol 1995, 281:161-171.
23. Roccon A, Marchionni D, Donat F, Segondy D, Cazaubon C, Nisato D: A pharmacodynamic study of SR 47436, a selective AT, receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br J Pharmacol 1994, 111:145-150.
24. 1 receptor antagonist in hypertensive rat models. Eur J Pharmacol 1994, 264:307-316.
25. Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K: Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetatesalt hypertensive rats. J Hypertens 1995, 13:113-122.
26. Ziai F, Ots M, Provoost AP, et al.: The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int 1996, 50 (suppl 57):S132-S136.
27. Hayakawa H, Coffee K, Guerra J, Raij L: Cardio-renal protection by the angiotensin II receptor antagonist irbesartan in salt-sensitive hypertension [abstract]. Am J Hypertens 1997, 10:94A.